PDT Partners LLC Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

PDT Partners LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 382.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 84,062 shares of the biopharmaceutical company’s stock after buying an additional 66,647 shares during the period. PDT Partners LLC’s holdings in Halozyme Therapeutics were worth $4,019,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in HALO. Norges Bank acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth $60,054,000. Capital World Investors acquired a new position in shares of Halozyme Therapeutics during the fourth quarter worth $35,773,000. Arrowstreet Capital Limited Partnership increased its position in shares of Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock worth $47,470,000 after purchasing an additional 581,475 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $21,838,000. Finally, Vanguard Group Inc. increased its position in shares of Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after acquiring an additional 386,618 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,697 shares of company stock worth $1,558,052. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 0.1 %

HALO stock opened at $60.57 on Tuesday. The company’s 50-day simple moving average is $60.56 and its 200-day simple moving average is $55.20. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 52-week low of $37.97 and a 52-week high of $66.00. The firm has a market cap of $7.48 billion, a P/E ratio of 17.66, a PEG ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on HALO. Wells Fargo & Company cut their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research report on Friday. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Benchmark reaffirmed a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.